Literature DB >> 30897009

Finasteride and androgenic alopecia; from therapeutic options to medical implications.

Ion G Motofei1,2, David L Rowland3, Mircea Tampa1, Maria-Isabela Sarbu1, Madalina-Irina Mitran1, Cristina-Iulia Mitran1, Anca Pantea Stoian4, Camelia C Diaconu4, Stana Paunica5, Simona R Georgescu1.   

Abstract

Androgenic alopecia (AGA) is an esthetic condition with varying psycho-social implications, easily accepted by some patients and tolerated only with difficulty by others. Modern therapeutic options such as 5α-reductase inhibitors have significant outcomes, but also exert significant side effects in a subset of patients. The literature describes three distinct situations regarding finasteride administration, a compound largely used for AGA. Some studies show finasteride to be very safe with minimal or no side effects. Other studies take a more cautious approach, recognizing such side effects but, at the same time, considering the putative relationship between finasteride and adverse effects to be disputable, given that placebo administration in AGA is associated with relatively similar or even more severe side effects. Finally, some authors/studies are concerned that, when compared to placebo, finasteride administration may result in side effects with greater frequency and severity, and sometimes that persist even after treatment cessation in the form of post-finasteride syndrome. Several factors presented in this paper appear to explain finasteride inconsistency regarding its therapeutic and side effects. Such factors should be further investigated and used to categorize subjects into distinct subgroups, either predisposed to adverse reactions or more tolerant of the finasteride administration.

Entities:  

Keywords:  Finasteride side effects; androgenic alopecia; medical implications; post-finasteride syndrome; therapeutic options

Mesh:

Substances:

Year:  2019        PMID: 30897009     DOI: 10.1080/09546634.2019.1595507

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  6 in total

Review 1.  Perspectives on miRNAs Targeting DKK1 for Developing Hair Regeneration Therapy.

Authors:  Dimitri Papukashvili; Nino Rcheulishvili; Cong Liu; Fengfei Xie; Deependra Tyagi; Yunjiao He; Peng George Wang
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

2.  The potential role of hsa_circ_0001079 in androgenetic alopecia via sponging hsa-miR-136-5p.

Authors:  Hanxiao Wei; Xiaoyu Xu; Shuai Yang; Chang Liu; Qiang Li; Peisheng Jin
Journal:  J Clin Lab Anal       Date:  2021-11-17       Impact factor: 2.352

3.  Dihydroartemisinin attenuates benign prostatic hyperplasia in rats by inhibiting prostatic epithelial cell proliferation.

Authors:  Bo Zhang; Xiang Chen; Yu Gan; Bing-Sheng Li; Kang-Ning Wang; Yao He
Journal:  Ann Transl Med       Date:  2021-08

4.  Hair Growth-Promoting Effect of Resveratrol in Mice, Human Hair Follicles and Dermal Papilla Cells.

Authors:  Yuting Zhang; Chunya Ni; Yan Huang; Yulong Tang; Kai Yang; Xiangguang Shi; Yue Zhang; Zheng Li; Ji'an Wang; Yifei Zhu; Haiyang Li; Yanyun Ma; Jinran Lin; Jiucun Wang; Qingmei Liu; Wenyu Wu
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-11-27

5.  Comprehensive Analysis of LncRNA AC010789.1 Delays Androgenic Alopecia Progression by Targeting MicroRNA-21 and the Wnt/β-Catenin Signaling Pathway in Hair Follicle Stem Cells.

Authors:  Jiachao Xiong; Baojin Wu; Qiang Hou; Xin Huang; Lingling Jia; Yufei Li; Hua Jiang
Journal:  Front Genet       Date:  2022-02-15       Impact factor: 4.599

Review 6.  Comorbidities in Androgenetic Alopecia: A Comprehensive Review.

Authors:  Shuang Chen; Xiaohang Xie; Guoqiong Zhang; Yong Zhang
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.